CAR-T cell therapy: cytokine release syndrome (CRS)
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
CAR-T cell therapy: cytokine release syndrome (CRS). CRS usually develops 2-3 days after infusion but can be delayed up to 14 days.
Pathology
- CRS usually develops 2-3 days after infusion but can be delayed up to 14 days
- It progresses over hours to days
- The severity is graded 1-4
Clinical features
Locked: subscribe to see this section.
Laboratory features: elevated indices
Locked: subscribe to see this section.
Complications
Locked: subscribe to see this section.
Treatment
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol 2020 (Online ahead of print).
- Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 2019; 34:45-55.
